Andra AP fonden Boosts Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Andra AP fonden boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 116.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 161,300 shares of the company’s stock after buying an additional 86,900 shares during the period. Andra AP fonden owned approximately 0.16% of Neurocrine Biosciences worth $22,206,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Neurocrine Biosciences by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock worth $1,369,673,000 after purchasing an additional 220,598 shares in the last quarter. Brown Advisory Inc. increased its stake in Neurocrine Biosciences by 2.2% in the 4th quarter. Brown Advisory Inc. now owns 1,113,413 shares of the company’s stock worth $146,703,000 after acquiring an additional 23,831 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Neurocrine Biosciences by 1.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company’s stock valued at $128,639,000 after acquiring an additional 13,069 shares in the last quarter. Vestal Point Capital LP purchased a new position in shares of Neurocrine Biosciences during the fourth quarter worth about $105,408,000. Finally, Allspring Global Investments Holdings LLC raised its stake in Neurocrine Biosciences by 40.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company’s stock valued at $97,828,000 after purchasing an additional 203,934 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on NBIX shares. Cantor Fitzgerald decreased their price target on shares of Neurocrine Biosciences from $170.00 to $155.00 and set an “overweight” rating on the stock in a report on Thursday, August 29th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research note on Thursday, August 29th. Barclays dropped their price target on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research note on Monday. BMO Capital Markets cut their price objective on Neurocrine Biosciences from $142.00 to $128.00 and set a “market perform” rating for the company in a report on Thursday, August 29th. Finally, Oppenheimer raised their price objective on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $162.20.

Insider Activity

In related news, insider Julie Cooke sold 12,632 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $153.26, for a total value of $1,935,980.32. Following the sale, the insider now owns 18,202 shares in the company, valued at approximately $2,789,638.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Gary A. Lyons sold 930 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $150.03, for a total value of $139,527.90. Following the transaction, the director now owns 119,047 shares in the company, valued at $17,860,621.41. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Julie Cooke sold 12,632 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $153.26, for a total transaction of $1,935,980.32. Following the sale, the insider now directly owns 18,202 shares of the company’s stock, valued at approximately $2,789,638.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,798 shares of company stock worth $10,676,096. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Up 0.4 %

NBIX opened at $120.64 on Tuesday. The stock has a market cap of $12.18 billion, a PE ratio of 33.23 and a beta of 0.37. The business has a 50 day moving average of $142.33 and a 200-day moving average of $139.01. Neurocrine Biosciences, Inc. has a 52 week low of $103.63 and a 52 week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The business had revenue of $590.20 million for the quarter, compared to the consensus estimate of $545.98 million. During the same quarter last year, the firm posted $0.95 EPS. The business’s quarterly revenue was up 30.4% on a year-over-year basis. Equities analysts anticipate that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.